U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe By Reuters

U.S. House Oversight Committee to subpoena AbbVie in drug-pricing probe


© Reuters. FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Stock Exchange

(Reuters) – The U.S. House Oversight Committee has decided to subpoena drugmaker Abbvie Inc to seek documents as part of its investigation into drug pricing practices.

“After more than 18 months, AbbVie (NYSE:) has demonstrated its unwillingness to comply voluntarily with the Committee’s investigation,” Representative Carolyn Maloney, the Chairwoman of the committee, wrote in a memo.

AbbVie did not immediately respond to Reuters request for comment.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME